Skip to main content
Top
Published in: Journal of Cardiovascular Translational Research 5/2022

21-03-2022 | Anthracycline | Review

In Vivo Murine Models of Cardiotoxicity Due to Anticancer Drugs: Challenges and Opportunities for Clinical Translation

Authors: Serena L’Abbate, Michela Chianca, Iacopo Fabiani, Annamaria Del Franco, Alberto Giannoni, Giuseppe Vergaro, Chrysanthos Grigoratos, Claudia Kusmic, Claudio Passino, Yuri D’Alessandra, Silvia Burchielli, Michele Emdin, Daniela Maria Cardinale

Published in: Journal of Cardiovascular Translational Research | Issue 5/2022

Login to get access

Abstract

Modern therapeutic approaches have led to an improvement in the chances of surviving a diagnosis of cancer. However, this may come with side effects, with patients experiencing adverse cardiovascular events or exacerbation of underlying cardiovascular disease related to their cancer treatment. Rodent models of chemotherapy-induced cardiotoxicity are useful to define pathophysiological mechanisms of cardiac damage and to identify potential therapeutic targets. The key mechanisms involved in cardiotoxicity induced by specific different antineoplastic agents are summarized in this state-of-the-art review, as well as the rodent models of cardiotoxicity by different classes of anticancer drugs, along with the strategies tested for primary and secondary cardioprotection. Current approaches for early detection of cardiotoxicity in preclinical studies with a focus on the application of advanced imaging modalities and biomarker strategies are also discussed.

Graphical abstract

Potential applications of cardiotoxicity modelling in rodents are illustrated in relation to the advancements of promising research topics of cardiotoxicity. Created with BioRender.com.
Literature
1.
go back to reference Plana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer-Crosbie, M., et al. (2014). Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. European Heart Journal Cardiovascular Imaging, 15(10), 1063–1093. https://doi.org/10.1093/ehjci/jeu192CrossRefPubMedPubMedCentral Plana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer-Crosbie, M., et al. (2014). Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. European Heart Journal Cardiovascular Imaging, 15(10), 1063–1093. https://​doi.​org/​10.​1093/​ehjci/​jeu192CrossRefPubMedPubMedCentral
2.
go back to reference Curigliano, G., Cardinale, D., Suter, T., Plataniotis, G., De Azambuja, E., Sandri, M. T., et al. (2012). Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines. Annals of Oncology, 23(SUPPL. 7). https://doi.org/10.1093/annonc/mds293 Curigliano, G., Cardinale, D., Suter, T., Plataniotis, G., De Azambuja, E., Sandri, M. T., et al. (2012). Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines. Annals of Oncology, 23(SUPPL. 7). https://​doi.​org/​10.​1093/​annonc/​mds293
8.
14.
go back to reference Schlaak, R. A., Frei, A., Schottstaedt, A. M., Tsaih, S. W., Fish, B. L., Harmann, L., et al. (2019). Mapping genetic modifiers of radiation-induced cardiotoxicity to rat chromosome 3. American Journal of Physiology - Heart and Circulatory Physiology, 316(6). https://doi.org/10.1152/ajpheart.00482.2018 Schlaak, R. A., Frei, A., Schottstaedt, A. M., Tsaih, S. W., Fish, B. L., Harmann, L., et al. (2019). Mapping genetic modifiers of radiation-induced cardiotoxicity to rat chromosome 3. American Journal of Physiology - Heart and Circulatory Physiology, 316(6). https://​doi.​org/​10.​1152/​ajpheart.​00482.​2018
16.
22.
23.
go back to reference Lu, Z., Wu, C. Y. C., Jiang, Y. P., Ballou, L. M., Clausen, C., Cohen, I. S., & Lin, R. Z. (2012). Suppression of phosphoinositide 3-kinase signaling and alteration of multiple ion currents in drug-induced long QT syndrome. Science Translational Medicine, 4(131). https://doi.org/10.1126/scitranslmed.3003623 Lu, Z., Wu, C. Y. C., Jiang, Y. P., Ballou, L. M., Clausen, C., Cohen, I. S., & Lin, R. Z. (2012). Suppression of phosphoinositide 3-kinase signaling and alteration of multiple ion currents in drug-induced long QT syndrome. Science Translational Medicine, 4(131). https://​doi.​org/​10.​1126/​scitranslmed.​3003623
28.
go back to reference Polegato, B. F., Minicucci, M. F., Azevedo, P. S., Carvalho, R. F., Chiuso-Minicucci, F., Pereira, E. J., et al. (2015). Acute doxorubicin-induced cardiotoxicity is associated with matrix metalloproteinase-2 alterations in rats. Cellular Physiology and Biochemistry, 35(5), 1924–1933. https://doi.org/10.1159/000374001CrossRefPubMed Polegato, B. F., Minicucci, M. F., Azevedo, P. S., Carvalho, R. F., Chiuso-Minicucci, F., Pereira, E. J., et al. (2015). Acute doxorubicin-induced cardiotoxicity is associated with matrix metalloproteinase-2 alterations in rats. Cellular Physiology and Biochemistry, 35(5), 1924–1933. https://​doi.​org/​10.​1159/​000374001CrossRefPubMed
31.
go back to reference De Carvalho, P. B., Gonçalves, A. D. F., Alegre, P. H. C., Azevedo, P. S., Roscani, M. G., Bergamasco, C. M., et al. (2016). Pamidronate attenuates oxidative stress and energetic metabolism changes but worsens functional outcomes in acute doxorubicin-induced cardiotoxicity in rats. Cellular Physiology and Biochemistry, 40(3–4), 431–442. https://doi.org/10.1159/000452558CrossRefPubMed De Carvalho, P. B., Gonçalves, A. D. F., Alegre, P. H. C., Azevedo, P. S., Roscani, M. G., Bergamasco, C. M., et al. (2016). Pamidronate attenuates oxidative stress and energetic metabolism changes but worsens functional outcomes in acute doxorubicin-induced cardiotoxicity in rats. Cellular Physiology and Biochemistry, 40(3–4), 431–442. https://​doi.​org/​10.​1159/​000452558CrossRefPubMed
32.
go back to reference O’Connell, J. L., Romano, M. M. D., Campos Pulici, E. C., Carvalho, E. E. V., de Souza, F. R., Tanaka, D. M., et al. (2017). Short-term and long-term models of doxorubicin-induced cardiomyopathy in rats: A comparison of functional and histopathological changes. Experimental and Toxicologic Pathology, 69(4), 213–219. https://doi.org/10.1016/j.etp.2017.01.004CrossRefPubMed O’Connell, J. L., Romano, M. M. D., Campos Pulici, E. C., Carvalho, E. E. V., de Souza, F. R., Tanaka, D. M., et al. (2017). Short-term and long-term models of doxorubicin-induced cardiomyopathy in rats: A comparison of functional and histopathological changes. Experimental and Toxicologic Pathology, 69(4), 213–219. https://​doi.​org/​10.​1016/​j.​etp.​2017.​01.​004CrossRefPubMed
33.
37.
go back to reference Bertinchant, J. P., Polge, A., Juan, J. M., Oliva-Lauraire, M. C., Giuliani, I., Marty-Double, C., et al. (2003). Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy rats, and their relationship with echocardiographic and histological findings. Clinica Chimica Acta, 329(1–2), 39–51. https://doi.org/10.1016/S0009-8981(03)00013-5CrossRef Bertinchant, J. P., Polge, A., Juan, J. M., Oliva-Lauraire, M. C., Giuliani, I., Marty-Double, C., et al. (2003). Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy rats, and their relationship with echocardiographic and histological findings. Clinica Chimica Acta, 329(1–2), 39–51. https://​doi.​org/​10.​1016/​S0009-8981(03)00013-5CrossRef
40.
go back to reference Hayward, R., & Hydock, D. S. (2007). Doxorubicin cardiotoxicity in the rat: An in vivo characterization. Journal of the American Association for Laboratory Animal Science, 46(4), 20–32.PubMed Hayward, R., & Hydock, D. S. (2007). Doxorubicin cardiotoxicity in the rat: An in vivo characterization. Journal of the American Association for Laboratory Animal Science, 46(4), 20–32.PubMed
48.
54.
55.
go back to reference Akolkar, G., Bhullar, N., Bews, H., Shaikh, B., Premecz, S., Bordun, K. A., et al. (2015). The role of renin angiotensin system antagonists in the prevention of doxorubicin and trastuzumab induced cardiotoxicity. Cardiovascular Ultrasound, 13(1). https://doi.org/10.1186/s12947-015-0011-x Akolkar, G., Bhullar, N., Bews, H., Shaikh, B., Premecz, S., Bordun, K. A., et al. (2015). The role of renin angiotensin system antagonists in the prevention of doxorubicin and trastuzumab induced cardiotoxicity. Cardiovascular Ultrasound, 13(1). https://​doi.​org/​10.​1186/​s12947-015-0011-x
66.
go back to reference Curwen, J. O., Musgrove, H. L., Kendrew, J., Richmond, G. H. P., Ogilvie, D. J., & Wedge, S. R. (2008). Inhibition of vascular endothelial growth factor-A signaling induces hypertension: Examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy. Clinical Cancer Research, 14(10), 3124–3131. https://doi.org/10.1158/1078-0432.CCR-07-4783CrossRefPubMed Curwen, J. O., Musgrove, H. L., Kendrew, J., Richmond, G. H. P., Ogilvie, D. J., & Wedge, S. R. (2008). Inhibition of vascular endothelial growth factor-A signaling induces hypertension: Examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy. Clinical Cancer Research, 14(10), 3124–3131. https://​doi.​org/​10.​1158/​1078-0432.​CCR-07-4783CrossRefPubMed
68.
go back to reference Bordun, K. A., Premecz, S., DaSilva, M., Mandal, S., Goyal, V., Glavinovic, T., et al. (2015). The utility of cardiac biomarkers and echocardiography for the early detection of bevacizumab- and sunitinib-mediated cardiotoxicity. American Journal of Physiology - Heart and Circulatory Physiology, 309(4), H692–H701. https://doi.org/10.1152/ajpheart.00172.2015CrossRefPubMed Bordun, K. A., Premecz, S., DaSilva, M., Mandal, S., Goyal, V., Glavinovic, T., et al. (2015). The utility of cardiac biomarkers and echocardiography for the early detection of bevacizumab- and sunitinib-mediated cardiotoxicity. American Journal of Physiology - Heart and Circulatory Physiology, 309(4), H692–H701. https://​doi.​org/​10.​1152/​ajpheart.​00172.​2015CrossRefPubMed
72.
go back to reference Stuhlmiller, T. J., Zawistowski, J. S., Chen, X., Sciaky, N., Angus, S. P., Hicks, S. T., et al. (2017). Kinome and transcriptome profiling reveal broad and distinct activities of erlotinib, sunitinib, and sorafenib in the mouse heart and suggest cardiotoxicity from combined signal transducer and activator of transcription and epidermal growth factor receptor inhibition. Journal of the American Heart Association, 6(10). https://doi.org/10.1161/JAHA.117.006635 Stuhlmiller, T. J., Zawistowski, J. S., Chen, X., Sciaky, N., Angus, S. P., Hicks, S. T., et al. (2017). Kinome and transcriptome profiling reveal broad and distinct activities of erlotinib, sunitinib, and sorafenib in the mouse heart and suggest cardiotoxicity from combined signal transducer and activator of transcription and epidermal growth factor receptor inhibition. Journal of the American Heart Association, 6(10). https://​doi.​org/​10.​1161/​JAHA.​117.​006635
78.
go back to reference Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995). Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity, 3(5). https://doi.org/10.1016/1074-7613(95)90125-6 Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995). Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity, 3(5). https://​doi.​org/​10.​1016/​1074-7613(95)90125-6
84.
go back to reference Herman, E. H., Lipshultz, S. E., Rifai, N., Zhang, J., Papoian, T., Yu, Z. X., et al. (1998). Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity. Cancer Research, 58(2), 195–197.PubMed Herman, E. H., Lipshultz, S. E., Rifai, N., Zhang, J., Papoian, T., Yu, Z. X., et al. (1998). Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity. Cancer Research, 58(2), 195–197.PubMed
89.
go back to reference Demissei, B. G., Hubbard, R. A., Zhang, L., Smith, A. M., Sheline, K., McDonald, C., et al. (2020). Changes in cardiovascular biomarkers with breast cancer therapy and associations with cardiac dysfunction. Journal of the American Heart Association, 9(2). https://doi.org/10.1161/JAHA.119.014708 Demissei, B. G., Hubbard, R. A., Zhang, L., Smith, A. M., Sheline, K., McDonald, C., et al. (2020). Changes in cardiovascular biomarkers with breast cancer therapy and associations with cardiac dysfunction. Journal of the American Heart Association, 9(2). https://​doi.​org/​10.​1161/​JAHA.​119.​014708
96.
go back to reference Fabiani, I., Pugliese, N. R., Santini, V., Conte, L., & Di Bello, V. (2016). Speckle-tracking imaging, principles and clinical applications: a review for clinical cardiologists. In Echocardiography in Heart Failure and Cardiac Electrophysiology. https://doi.org/10.5772/64261 Fabiani, I., Pugliese, N. R., Santini, V., Conte, L., & Di Bello, V. (2016). Speckle-tracking imaging, principles and clinical applications: a review for clinical cardiologists. In Echocardiography in Heart Failure and Cardiac Electrophysiology. https://​doi.​org/​10.​5772/​64261
97.
go back to reference Farhad, H., Staziaki, P. V., Addison, D., Coelho-Filho, O. R., Shah, R. V., Mitchell, R. N., et al. (2016). Characterization of the changes in cardiac structure and function in mice treated with anthracyclines using serial cardiac magnetic resonance imaging. Circulation: Cardiovascular Imaging, 9(12). https://doi.org/10.1161/CIRCIMAGING.115.003584 Farhad, H., Staziaki, P. V., Addison, D., Coelho-Filho, O. R., Shah, R. V., Mitchell, R. N., et al. (2016). Characterization of the changes in cardiac structure and function in mice treated with anthracyclines using serial cardiac magnetic resonance imaging. Circulation: Cardiovascular Imaging, 9(12). https://​doi.​org/​10.​1161/​CIRCIMAGING.​115.​003584
98.
go back to reference Lightfoot, J. C., D’Agostino, R. B., Hamilton, C. A., Jordan, J., Torti, F. M., Kock, N. D., et al. (2010). Novel approach to early detection of doxorubicin cardiotoxicity by gadolinium-enhanced cardiovascular magnetic resonance imaging in an experimental model. Circulation: Cardiovascular Imaging, 3(5), 550–558. https://doi.org/10.1161/CIRCIMAGING.109.918540CrossRef Lightfoot, J. C., D’Agostino, R. B., Hamilton, C. A., Jordan, J., Torti, F. M., Kock, N. D., et al. (2010). Novel approach to early detection of doxorubicin cardiotoxicity by gadolinium-enhanced cardiovascular magnetic resonance imaging in an experimental model. Circulation: Cardiovascular Imaging, 3(5), 550–558. https://​doi.​org/​10.​1161/​CIRCIMAGING.​109.​918540CrossRef
99.
go back to reference Herman, E., Ardalan, B., Bier, C., Waravdekar, V., & Krop, S. (1979). Reduction of daunorubicin lethality and myocardial cellular alterations by pretreatment with ICRF-187 in Syrian golden hamsters. Cancer Treatment Reports, 63(1), 89–92.PubMed Herman, E., Ardalan, B., Bier, C., Waravdekar, V., & Krop, S. (1979). Reduction of daunorubicin lethality and myocardial cellular alterations by pretreatment with ICRF-187 in Syrian golden hamsters. Cancer Treatment Reports, 63(1), 89–92.PubMed
101.
go back to reference Lódi, M., Priksz, D., Fülöp, G. Á., Bódi, B., Gyöngyösi, A., Nagy, L., et al. (2019). Advantages of prophylactic versus conventionally scheduled heart failure therapy in an experimental model of doxorubicin-induced cardiomyopathy. Journal of Translational Medicine, 17(1). https://doi.org/10.1186/s12967-019-1978-0 Lódi, M., Priksz, D., Fülöp, G. Á., Bódi, B., Gyöngyösi, A., Nagy, L., et al. (2019). Advantages of prophylactic versus conventionally scheduled heart failure therapy in an experimental model of doxorubicin-induced cardiomyopathy. Journal of Translational Medicine, 17(1). https://​doi.​org/​10.​1186/​s12967-019-1978-0
102.
go back to reference Lódi, M., Bánhegyi, V., Bódi, B., Gyöngyösi, A., Kovács, Á., Árokszállási, A., et al. (2020). Prophylactic, single-drug cardioprotection in a comparative, experimental study of doxorubicin-induced cardiomyopathy. Journal of Translational Medicine, 18(1). https://doi.org/10.1186/s12967-020-02564-w Lódi, M., Bánhegyi, V., Bódi, B., Gyöngyösi, A., Kovács, Á., Árokszállási, A., et al. (2020). Prophylactic, single-drug cardioprotection in a comparative, experimental study of doxorubicin-induced cardiomyopathy. Journal of Translational Medicine, 18(1). https://​doi.​org/​10.​1186/​s12967-020-02564-w
109.
go back to reference Iqbal, M., Dubey, K., Anwer, T., Ashish, A., & Pillai, K. K. (2008). Protective effects of telmisartan against acute doxorubicin-induced cardiotoxicity in rats. Pharmacological Reports, 60(3), 382–390.PubMed Iqbal, M., Dubey, K., Anwer, T., Ashish, A., & Pillai, K. K. (2008). Protective effects of telmisartan against acute doxorubicin-induced cardiotoxicity in rats. Pharmacological Reports, 60(3), 382–390.PubMed
117.
go back to reference Bernstein, D., Fajardo, G., Zhao, M., Urashima, T., Powers, J., Berry, G., & Kobilka, B. K. (2005). Differential cardioprotective/cardiotoxic effects mediated by β-adrenergic receptor subtypes. American Journal of Physiology - Heart and Circulatory Physiology, 289(6 58–6). https://doi.org/10.1152/ajpheart.00005.2005 Bernstein, D., Fajardo, G., Zhao, M., Urashima, T., Powers, J., Berry, G., & Kobilka, B. K. (2005). Differential cardioprotective/cardiotoxic effects mediated by β-adrenergic receptor subtypes. American Journal of Physiology - Heart and Circulatory Physiology, 289(6 58–6). https://​doi.​org/​10.​1152/​ajpheart.​00005.​2005
120.
go back to reference Feleszko, W., Młynarczuk, I., Bałkowiec-Iskra, E. Z., Czajka, A., Świtaj, T., Stokłosa, T., et al. (2000). Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice. Clinical Cancer Research, 6(5), 2044–2052.PubMed Feleszko, W., Młynarczuk, I., Bałkowiec-Iskra, E. Z., Czajka, A., Świtaj, T., Stokłosa, T., et al. (2000). Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice. Clinical Cancer Research, 6(5), 2044–2052.PubMed
121.
129.
go back to reference Ibrahim, M. A., Bakhaat, G. A., Tammam, H. G., Mohamed, R. M., & El-Naggar, S. A. (2019). Cardioprotective effect of green tea extract and vitamin E on Cisplatin-induced cardiotoxicity in mice: Toxicological, histological and immunohistochemical studies. Biomedicine and Pharmacotherapy, 113. https://doi.org/10.1016/j.biopha.2019.108731 Ibrahim, M. A., Bakhaat, G. A., Tammam, H. G., Mohamed, R. M., & El-Naggar, S. A. (2019). Cardioprotective effect of green tea extract and vitamin E on Cisplatin-induced cardiotoxicity in mice: Toxicological, histological and immunohistochemical studies. Biomedicine and Pharmacotherapy, 113https://​doi.​org/​10.​1016/​j.​biopha.​2019.​108731
Metadata
Title
In Vivo Murine Models of Cardiotoxicity Due to Anticancer Drugs: Challenges and Opportunities for Clinical Translation
Authors
Serena L’Abbate
Michela Chianca
Iacopo Fabiani
Annamaria Del Franco
Alberto Giannoni
Giuseppe Vergaro
Chrysanthos Grigoratos
Claudia Kusmic
Claudio Passino
Yuri D’Alessandra
Silvia Burchielli
Michele Emdin
Daniela Maria Cardinale
Publication date
21-03-2022
Publisher
Springer US
Published in
Journal of Cardiovascular Translational Research / Issue 5/2022
Print ISSN: 1937-5387
Electronic ISSN: 1937-5395
DOI
https://doi.org/10.1007/s12265-022-10231-2

Other articles of this Issue 5/2022

Journal of Cardiovascular Translational Research 5/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine